Inventia Healthcare Limited — Fenofibrate Exporter Profile
Indian Pharmaceutical Exporter · #12 for Fenofibrate · $1.4M export value · DGFT Verified
Inventia Healthcare Limited is the #12 Indian exporter of Fenofibrate with $1.4M in export value and 60 verified shipments. Inventia Healthcare Limited holds a 2.0% market share in Fenofibrate exports across 4 countries. The company exports 11 pharmaceutical products worth $36.5M across 6 therapeutic categories.
Inventia Healthcare Limited — Fenofibrate Export Profile: Buyers & Destinations
Where Does Inventia Healthcare Limited Export Fenofibrate?
| Country | Value | Shipments | Share |
|---|---|---|---|
| UNITED STATES | $838.9K | 23 | 67.7% |
| MYANMAR | $332.7K | 28 | 26.9% |
| VIETNAM, DEMOCRATIC REP. OF | $41.4K | 6 | 3.3% |
| VIETNAM DEMOCRATIC REP. OF | $15.0K | 1 | 1.2% |
| VIETNAM | $7.8K | 1 | 0.6% |
| CAMBODIA | $2.6K | 1 | 0.2% |
Inventia Healthcare Limited exports Fenofibrate to 6 countries. The largest destination is UNITED STATES accounting for 67.7% of Inventia Healthcare Limited's Fenofibrate shipments, followed by MYANMAR (26.9%) and VIETNAM, DEMOCRATIC REP. OF (3.3%). These destinations reflect Inventia Healthcare Limited's established distribution network and regulatory approvals in key markets.
Who Are the Top Buyers of Fenofibrate from Inventia Healthcare Limited?
| Buyer | Country | Value | Orders |
|---|---|---|---|
| ANIP ACQUISITION COMPANY | UNITED STATES | $711.8K | 20 |
| MYIT MAHAR TRADING CO LTD | MYANMAR | $139.7K | 9 |
| EVERSANA | UNITED STATES | $127.1K | 3 |
| MYIT MAHAR TRADING CO., LTD | MYANMAR | $51.1K | 3 |
| LWIN AND MYINT TRADING COMPANY LIM | MYANMAR | $45.5K | 2 |
| LWIN AND MYINT TRADING COMPANY LIMI | MYANMAR | $38.5K | 7 |
| MAXXCARE COMPANY LIMITED. | VIETNAM, DEMOCRATIC REP. OF | $31.0K | 3 |
| MYIT MAHAR TRADING CO LIMITED | MYANMAR | $27.8K | 2 |
| LWIN AND MYINT TRADING CO LTD | MYANMAR | $15.0K | 2 |
| LWIN AND MYINT TRADING COMPANY | MYANMAR | $15.0K | 3 |
Inventia Healthcare Limited supplies Fenofibrate to 14 buyers globally. The largest buyer is ANIP ACQUISITION COMPANY (UNITED STATES), followed by MYIT MAHAR TRADING CO LTD (MYANMAR) and EVERSANA (UNITED STATES). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
What Is India's Total Fenofibrate Export Value and How Much Does Inventia Healthcare Limited Contribute?
India exported $48.1M worth of Fenofibrate through 2,794 shipments from 168 suppliers to 81 countries, serving 368 buyers globally. Inventia Healthcare Limited contributes $1.4M to this total, accounting for 2.0% of India's Fenofibrate exports. Inventia Healthcare Limited ships Fenofibrate to 6 countries through 14 buyers.
What Is the Average Shipment Value for Inventia Healthcare Limited's Fenofibrate Exports?
Inventia Healthcare Limited's average Fenofibrate shipment value is $24.0K per consignment, based on 60 shipments totaling $1.4M. The largest destination is UNITED STATES (67.7% of Inventia Healthcare Limited's Fenofibrate exports).
How Does Inventia Healthcare Limited Compare to Other Indian Fenofibrate Exporters?
Inventia Healthcare Limited ranks #12 among 168 Indian Fenofibrate exporters with a 2.0% market share. The top 3 exporters are HETERO LABS LIMITED ($8.3M), CIPLA LIMITED ($7.1M), SUN PHARMACEUTICAL INDUSTRIES LIMITED ($5.7M). Inventia Healthcare Limited processed 60 shipments to 4 destination countries.
What Fenofibrate Formulations Does Inventia Healthcare Limited Export?
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| PHARMACEUTICAL MATERIALS- FENOFIBRATE CA | $200.0K | 4 |
| PHARMACEUTICAL MATERIALS FENOFIBRATE CAP | $127.1K | 3 |
| PHARMACEUTICAL MATERIALS FENOFIBRATE CAPSULES USP 134 MG 100S NDC NO. 439753051 | $95.4K | 2 |
| BRANDTONACT FN ATORVASTATIN 10 MG ANDFENOFIBRATE 160 MG TABLETS PACK 10 X 10 NOS CARTON | $50.0K | 2 |
| PHARMACEUTICAL MATERIALS - FENOFIBRATE CAPSULES USP 134 MG 100'S 1X100 NDC NO. 4397530510 | $50.0K | 1 |
| BRANDTONACT FN (ATORVASTATIN 10 MG ANDFENOFIBRATE 160 MG TABLETS) (PACK SIZE10X10)(NOS=CARTONS)NOS | $50.0K | 1 |
| FENOFIBRATE CAPSULES USP 200 MG 100' NDC NO. 4397530610 (1X100 ) | $50.0K | 1 |
| PHARMACEUTICAL MATERIALS - FENOFIBRATE CAPSULES USP 134 MG 100'S NDC NO. 43975-305-10 | $50.0K | 1 |
| COLESTRIM (EACH FILM COATED TABLETCONTAIN FENOFIBRATE B.P.160MG) | $45.5K | 2 |
| BRAND:TONACT FN (ATORVASTATIN 10 MG AND FENOFIBRATE 160 MG TABLETS)(PACK SIZE:10X10)(NOS=CARTON) | $45.0K | 1 |
Inventia Healthcare Limited exports 39 distinct Fenofibrate formulations including tablets, capsules, syrups, and combination drugs. The top formulation is PHARMACEUTICAL MATERIALS- FENOFIBRATE CA with 4 shipments worth $200.0K. Notable combination products include fixed-dose combinations with other active ingredients, meeting diverse global regulatory requirements.
Regulatory Requirements: Exporting Fenofibrate to Key Markets
What Inventia Healthcare Limited must comply with to export Fenofibrate to its top destination countries
United States — FDA
Approval Process
ANDA (Abbreviated New Drug Application) for generics. Indian manufacturing site must pass FDA pre-approval inspection. Drug Master File (DMF) required for APIs.
Timeline: 10–18 months for ANDA approval
GMP & Export Requirements
FDA cGMP compliance (21 CFR 210/211); facility inspection by FDA
Drug Listing with FDA; Export Certificate from CDSCO India; Import Alert screening via FDA PREDICT system
Note: Subject to FDA Import Alerts. Open Form 483 observations can block all exports from a facility.
Regulatory information is provided for general reference based on publicly available guidelines. Requirements vary by formulation, dosage form, and therapeutic classification. Exporters should consult qualified regulatory affairs professionals for case-specific guidance.
How Does Inventia Healthcare Limited Compare to Nearest Fenofibrate Exporters?
Exporters ranked immediately above and below #12 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 1 | ABBOTT HEALTHCARE PRIVATE LIMITED | $2.5M | 50 | 5 | $50.0K |
| 11 | ALEMBIC PHARMACEUTICALS LIMITED | $1.5M | 129 | 1 | $11.6K |
| 12 | INVENTIA HEALTHCARE LIMITED ★ | $1.4M | 60 | 4 | $24.0K |
| 14 | TORRENT PHARMACEUTICALS LTD | $1.4M | 41 | 5 | $34.6K |
| 10 | ABBOTT HEALTH CARE PRIVATE LIMITED | $500.0K | 10 | 2 | $50.0K |
Inventia Healthcare Limited ranks #12 among 168 Indian Fenofibrate exporters. Average shipment value of $24.0K compared to the market average of $286.5K. The closest competitors by value are ABBOTT HEALTHCARE PRIVATE LIMITED and ALEMBIC PHARMACEUTICALS LIMITED.
Which Indian Ports Ship Fenofibrate Exports?
| Port | Shipments | % Share |
|---|---|---|
| NHAVA SHEVA SEA (INNSA1) | 361 | 12.9% |
| SAHAR AIR | 281 | 10.1% |
| SAHAR AIR CARGO ACC (INBOM4) | 229 | 8.2% |
| DELHI AIR CARGO ACC (INDEL4) | 227 | 8.1% |
| JNPT/ NHAVA SHEVA SEA | 203 | 7.3% |
| DELHI AIR | 143 | 5.1% |
| HYDERABAD ICD | 125 | 4.5% |
| JNPT | 115 | 4.1% |
Geopolitical & Trade Policy Impact on Inventia Healthcare Limited's Fenofibrate Exports
Inventia Healthcare's extensive export operations are currently navigating a complex geopolitical landscape that presents both challenges and opportunities. The ongoing Israel-Iran tensions have led to disruptions in Red Sea shipping routes, resulting in increased freight costs and extended transit times. These logistical challenges are particularly impactful for time-sensitive pharmaceutical shipments, necessitating strategic adjustments in supply chain management to mitigate potential delays and cost escalations. (pharmaceuticalcommerce.com)
In the United States, recent tariff implementations have introduced additional complexities for Indian pharmaceutical exporters. The imposition of tariffs on a broad range of imports, including pharmaceuticals, has raised concerns about cost competitiveness and market access. Companies like Inventia must navigate these policy shifts by exploring alternative markets and enhancing operational efficiencies to maintain their competitive edge. (apnews.com)
Conversely, the European Union's stringent regulatory frameworks, such as the Falsified Medicines Directive, necessitate rigorous compliance measures. While these regulations impose additional operational requirements, they also present an opportunity for companies with robust quality systems to differentiate themselves. Inventia's adherence to international quality standards positions it favorably to meet these regulatory demands and strengthen its presence in the European market.
Inventia Healthcare Limited — Regulatory Compliance & Quality Standards
The global pharmaceutical industry is witnessing heightened regulatory scrutiny, with agencies like the U.S. FDA and the European Medicines Agency intensifying their focus on manufacturing practices and product quality. For Indian exporters, this translates into the necessity for stringent compliance with Good Manufacturing Practices (GMP) and other regulatory standards.
Inventia Healthcare's manufacturing facility in Ambernath and its research and development center in Thane are accredited by the U.S. FDA, U.K. MHRA, and other stringent regulatory authorities. This compliance underscores the company's commitment to maintaining high-quality standards, facilitating access to both emerging and regulated markets. (platinumequity.com)
However, the broader Indian pharmaceutical sector faces challenges related to quality assurance, with instances of regulatory non-compliance affecting the industry's reputation. To mitigate these risks, companies like Inventia must continually invest in quality control systems, employee training, and process improvements to ensure sustained compliance and market trust.
About Inventia Healthcare Limited
Inventia Healthcare Limited exports 11 products worth $36.5M. Beyond Fenofibrate, top products include Metformin, Telmisartan, Dapagliflozin, Glimepiride, Gliclazide. View the complete Inventia Healthcare Limited profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Fenofibrate — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Fenofibrate shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
- 2.Supplier Identification: Inventia Healthcare Limited matched across shipments using name normalization, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 4.Verified Records: This page is backed by 60 individual customs records matching Inventia Healthcare Limited exporting Fenofibrate, covering 39 formulations to 6 countries via 14 buyers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 81+ countries, 368+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Fenofibrate Export Data from Inventia Healthcare Limited
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Inventia Healthcare Limited's Fenofibrate exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Inventia Healthcare Limited
Full Company Profile →
11 products · $36.5M total trade · 6 categories
Fenofibrate Stats
Company Overview
Top Products by Inventia Healthcare Limited
Related Analysis
Need Detailed Export Data?
Access shipment-level records, pricing trends, and buyer contacts for Inventia Healthcare Limited.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Fenofibrate. For current shipment-level data, contact TransData Nexus.